4th Annual European Congress on Immunotherapies in Cancer™
The clinical development of immunotherapies is undoubtedly one of the most prominent topics in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. While the integration of landmark trial data and new strategies is occurring on an ongoing basis, preclinical and clinical data on immunotherapy basic science continue to rapidly accumulate.
The rapid pace with which new and practice-changing information is emerging creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence of immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.
The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on scientific advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.
Download the Program Flyer
This educational activity is intended for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.
At the conclusion of this activity, you should be better prepared to:
- Describe targets and mechanisms of immunotherapeutic agents in oncology
- Identify key findings of recent clinical trials relevant to immunotherapy across malignancies
- Outline ongoing studies of immunotherapy and the gaps in understanding of efficacy and safety these trials are meant to address
- List biomarkers and patient-specific factors that may affect response to immunotherapeutic treatment
- Define evidence-based treatment strategies to mitigate and prevent immune-mediated adverse events with of immunotherapeutic agents across malignancies
Professor of Medicine
Professor of Surgery
Professor of Molecular and Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program,
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Chair, Melanoma Committee at SWOG
Los Angeles, CA, USA
Professor of Dermatology
Head of the Dermatology Unit
Department of Medicine
Institut Gustave Roussy
RegistrationDaily Conference Rates Available – Contact us for details
Physicians' Education Resource - ECIC 19
2 Clarke Drive, Suite 110
Cranbury, NJ 08512
|Physicians||EUR €199||EUR €249|
|Fellows*||Complimentary Registration*||Complimentary Registration*|
|Nurses, PAs, Other Health Care Professionals||EUR €199||EUR €249|
|Industry**||EUR €499||EUR €599|
*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. Cannot be combined with other discounts/coupon codes.
**INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.
For registration assistance, please e-mail firstname.lastname@example.org or call +1 (609) 378-3701 between 9:00 and 17:00 US EDT.
A cancellation fee of 25% will be assessed on refunds requested prior to 4 October 2019 and a 50% fee on refunds requested 5 October 2019 through 1 November 2019. No refunds will be made after 1 November 2019. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.
In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.
Physicians' Education Resource®, LLC, reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting continuing education materials.
By attending a PER® conference, meeting, or related activity (“events”), all participants, attendees, exhibitors, sponsors, and guests (“you”) create an agreement between you and PER® regarding the use and distribution of your image, including, but not limited to, your name, voice, and likeness (“image”). By attending the events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you, and you grant permission to PER® (and its agents) to utilize, in perpetuity, your image in any electronic or print distribution or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with all applicable laws, rules, and regulations, and as such, we may be required to collect information on transfer of value provided to healthcare professionals or healthcare organizations.
You must be logged in to PER to register for this meeting
Or Register for PER now
In case of onsite emergency:
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.